Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00408-5/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=lancetcovid22&utm_medium=email&_hsmi=283901121&_hsenc=p2ANqtz-9noWHo9MLprf_A874gAXYTCqx-rBAToV2fJOlOGfSL9Pnuj6LdiMPGztZGKd33U6oX4fuhgi9kC-BR5M4RBvW9TtrfGA&utm_content=283899141&utm_source=hs_email